Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_4_suppst4.xlsx › Sheet2
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Tiedt R et al.
Cancer Research, 2011
21697284 (PubMed )
Supplement: 00085472can104433-sup-f2_t4_meth.pdf
Select a paper to view details